Evaluating Adverse Reactions of Central Venous Catheter Placement in Patients with AIDS: A Meta-Analysis Approach.

Objective:This study aims to identify contributing factors to adverse reactions related to central venous catheter (CVC) usage in patients with HIV/AIDS, to enhance patient care and treatment outcomes. Methods:To obtain the most relevant and recent findings, we conducted a systematic search across reputable databases, including PubMed, EMBASE, and the Cochrane Library, focusing on randomized controlled trials from 2010 to 2023. Two researchers independently led the literature search and screening process, using a thorough pre-structured form for data extraction and performing a risk of bias assessment on selected studies. Statistical synthesis of the data was conducted using the advanced Review Manager 5.3 software. We compared the prevalence of opportunistic infections, the rate of venous inflammation, and the incidence of venous thrombosis in patients with HIV/AIDS undergoing central venous catheter placement. Results:The comprehensive exploration led to the inclusion of seven randomized controlled trials, involving 251 instances of central venous catheter placements in patients with HIV/AIDS. The meta-analysis findings revealed a lower prevalence of opportunistic infections in patients with CVCs placed, as indicated by the relative risk [95% Confidence Interval (CI) (2.53), P < .01]. Similarly, the rate of venous inflammation was significantly reduced [95% CI (2.53), P < .01]. However, the rates of venous thrombosis showed no statistically significant variance [95% CI (2.01), P > .1]. Conclusions:The use of central venous catheters in treating HIV/AIDS patients appears to reduce the occurrence of opportunistic infections and venous inflammation, suggesting potential therapeutic benefits. However, the presence of biases within the included studies and notable heterogeneity among them impede the reliability of these conclusions. Therefore, it is imperative to pursue validation through additional high-quality clinical trials.